BigRNA
Proprietary foundation model trained on over a trillion signals from RNA sequencing datasets
Model · Api OnlyCompany source
Company profile
About Deep Genomics
Deep Genomics uses AI to discover and develop genetic medicines, identifying disease-causing genetic variants and designing therapies to correct them.
Company description Deep Genomics official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at Deep Genomics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- autism
- diseases requiring RNA-targeted therapeutics
- genetic disorders
- splicing defects
- Wilson disease
Who it serves
- Biotech
- Pharma
Deployment & integration
Api Only · Hybrid deployment with recorded integration context.
Geographic context
MarketsCanada · United States
Company sourceOfficial website
Company milestones
Platform expansion
REPRESS model announced May 2025; Executive hires including Monika Kowalczyk MD PhD as VP Platform Technology and Greg Hoffman PhD as CSO in April 2025; Thong Q. Le and Paul Sekhri joined Board of Directors October 2025; Cambridge MA office expansion June 2024; BigRNA foundation model launched 2021 with significant enhancements through 2025
Partnerships
Recorded partners
- major pharma partners (unnamed)
- Vector Institute for Artificial Intelligence (co-founded)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
BioFM Platform
AI-driven genetic medicines platform with lab-in-the-loop workflows for drug discovery
Platform · HybridCompany source
DeepADAR
AI model for designing guide RNAs to induce ADAR-mediated editing across trinucleotide contexts
Model · Api OnlyCompany source
REPRESS
Deep learning model predicting cell-type-specific microRNA binding and mRNA degradation from RNA sequence
Model · Api OnlyCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Novel and less invasive biomarker assays to measure liver ATP7B in Wilson disease patients.Scientific reports · Oct 28, 2025
Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry Recommendations.Nucleic acid therapeutics · Feb 1, 2025
Comprehensive whole-genome sequence analyses provide insights into the genomic architecture of cerebral palsy.Nature genetics · Apr 1, 2024
Gene copy number variation and pediatric mental health/neurodevelopment in a general population.Human molecular genetics · Jul 20, 2023
Biomarkers Associated With Severe COVID-19 Among Populations With High Cardiometabolic Risk: A 2-Sample Mendelian Randomization Study.JAMA network open · Jul 3, 2023
A curated census of pathogenic and likely pathogenic UTR variants and evaluation of deep learning models for variant effect prediction.Frontiers in molecular biosciences · Jan 1, 2023
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
BigRNA trained on over a trillion signals
Foundation model for RNA biology
Prediction resolution improved from 128-bp to 1-bp
BigRNA model evolution since 2021
16 million target sites analyzed
DeepADAR endogenous editing prediction
REPRESS outperforms other advanced methods
Comprehensive suite of orthogonal tasks including variant identification and reporter assay prediction
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from Deep Genomics
Recent articles published on Deep Genomics's official website.
From skeptic to builder: why I changed my mind about AI for biologyOctober 20, 2025Albi Celaj, Head of ML Research
Read on Deep GenomicsFrom skeptic to builder: why I changed my mind about AI for biology
Read on Deep GenomicsThe TechBio way: Brendan Frey talks genomics, AI, and RNA
Read on Deep GenomicsThe TechBio Way: Brendan Frey talks genomics, AI, and RNAAugust 14, 2025Brendan Frey
Read on Deep GenomicsWhy AI for drug discovery will far exceed current expectationsJune 18, 2025Brendan Frey
Read on Deep Genomics07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.